A phase I, open label, balanced, randomized, two-period (fasting versus fed), two-sequence, cross-over, single-dose food effect study of P2202 of Piramal Life Sciences Limited, India in healthy, adult, male human subjects.
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2016
Price : $35 *
At a glance
- Drugs P 2202 (Primary)
- Indications Metabolic syndrome
- Focus Pharmacokinetics
- Sponsors Piramal Enterprises
- 12 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India.
- 05 Oct 2012 New trial record